Back to top
more

Vertex Pharmaceuticals (VRTX)

(Real Time Quote from BATS)

$476.35 USD

476.35
532,245

+4.35 (0.92%)

Updated Aug 16, 2024 02:50 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (74 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

The company’s main area of focus is cystic fibrosis (CF). The company’s lead marketed products are Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor), Symdeko/Symkevi (tezacaftor in combination with ivacaftor), Orkambi (lumacaftor in combination with ivacaftor) and Kalydeco (ivacaftor), which are collectively approved to treat the majority of the people with CF in North America, Europe and Australia. Trikafta, Vertex’s triple combination regimen, was approved by the FDA in October 2019 for the treatment of CF in people aged 12 years and older who have at least one F508del mutation. Kaftrio (brand name of Trikafta in EU) was approved in the European Union in August 2020. It is also being evaluated in younger patients in the United States. With approval of Trikafta, Vertex can address a significantly larger CF patient population — almost 90% of patients with CF — in the future. Meanwhile, Vertex is pursuing genetic therapies to address the remaining 10% of CF patients. While CF remains the main area of focus, Vertex is also developing treatments for sickle cell disease, thalassemia and pain management.

5 Toxic Stocks to Remove from Your Portfolio or Play Short

by Zacks Equity Research

Elevated price levels of toxic stocks can be due to either an irrational exuberance associated with them or some serious fundamental lacunae.

    Arpita Dutt headshot

    Biotech Stock Roundup: Actelion Remains in M&A Spotlight, ASH Data in Focus

    by Arpita Dutt

    This week, several biotech companies were present at the annual meeting of the American Society of Hematology (ASH) with data on approved and pipeline candidates.

      Zacks.com featured highlights: Allegheny Technologies, salesforce.com, United States Steel, Vertex Pharmaceuticals and Continental Resources

      by Zacks Equity Research

      Zacks.com featured highlights: Allegheny Technologies, salesforce.com, United States Steel, Vertex Pharmaceuticals and Continental Resources

        Zacks Industry Outlook Highlights: Amgen, Vertex, Valeant Pharmaceuticals International, Mylan N.V. and Gilead Sciences

        by Zacks Equity Research

        Zacks Industry Outlook Highlights: Amgen, Vertex, Valeant Pharmaceuticals International, Mylan N.V. and Gilead Sciences

          Stock Market News for August 25, 2016

          by Zacks Equity Research

            by Zacks Equity Research

            The biotech segment has been growing well surpassing all expectations.

              Vertex Pharmaceuticals Posts Narrower-than-Expected Loss

              by Zacks Equity Research

              Vertex Pharmaceuticals's (VRTX) third-quarter 2014 loss came in at 56 cents per share wider than the year-ago loss of 46 cents.